Charlotte Hedin

Charlotte Hedin

Adjunct Lecturer
Visiting address: Eugeniavägen 11 B4:09, 17164 Solna
Postal address: K2 Medicin, Solna, K2 Reuma Hedin C, 171 77 Stockholm
Part of:

About me

  • Dr Charlotte Hedin is a specialist in gastroenterology and internal medicine
    at the Karolinska University Hospital in Stockholm. She completed her PhD
    "Microbial, immunological, phenotypic and genetic markers of risk: aspects of
    Crohn’s disease that are shared by unaffected siblings" at King’s College
    London and Queen Mary University of London. In 2017 she was awarded a UEG
    Rising Star award for her research in IBD and in 2018 she was awarded the
    Karolina prize for “Exemplary patient flow and quality work” at the
    Karolinska Hospital. She holds a clinical post-doctorate from the Karolinska
    Hospital. She is a member of the Swedish Organisation for the study of IBD
    (SOIBD)) and is committee member for the European Crohn’s and Colitis
    Organisation (ECCO). Dr Hedin’s research focusses on: 1. Extraintestinal
    inflammation in IBD inlcuding PSC, 2. Delineating pathogenic pathways in IBD
    through studying at-risk individuals (families of IBD patients) and 3.
    Defining the process of mucosal healing.
    2018 Karolina prize for “Exemplary patient flow and quality work”
    2017 UEG Rising Star Award
    2016 Swedish Medical Society prize for best scientific application
    2013 Prize for best inflammatory bowel disease oral presentation of an
    abstract at the British Society of Gastroenterology Annual Meeting
    2011 First prize in the oral presentation competition in the King’s College
    London Postgraduate Research Symposium
    2010 Runner-up in poster competition King’s College London Postgraduate
    Research Symposium
    2004 British Infection Society Spring Meeting presentation prize

Research

  • Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter
    M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH,
    Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der
    Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M,
    Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A,
    Beretta-Piccoli BT, Rogers JK
  • International Primary Sclerosing Cholangitis
    Study Group (IPSCSG), Levy C. Effects of Vedolizumab in Patients With Primary
    Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol
    Hepatol. 2020 Jan
  • 18(1):179-187
    Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U,
    Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A,
    Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D,
    Becker MD, Bamias G, Rieder F. The Pathogenesis of Extraintestinal
    Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J
    Crohns Colitis. 2019 Apr 26
  • 13(5):541-554.
    Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ,
    Lindsay JO, Whelan K. Siblings of patients with Crohn's disease exhibit a
    biologically relevant dysbiosis in mucosal microbial metacommunities. Gut.
    2016 Jun
  • 65(6):944-53
    Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K,
    Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO. Altered intestinal
    microbiota and blood T cell phenotype are shared by patients with Crohn's
    disease and their unaffected siblings. Gut. 2014 Oct
  • 63(10):1578-86
    Hedin CRH, Stagg AJ, Whelan K, Lindsay JO. Family studies in Crohn’s
    disease: New horizons in understanding disease pathogenesis, risk and
    prevention. Gut 2012
  • 61: 311-318
    Hedin CRH, Mullard M, Sharratt E, Jansen C, Sanderson JD, Shirlaw P, Howe LC,
    Djemal S, Stagg AJ, Lindsay JO and Whelan K Probiotic and Prebiotic Use in
    Patients with Inflammatory Bowel Disease: A Case-Control Study. Inflammatory
    Bowel Diseases 2010
  • 16(12): 2099-108
    Hedin C, Whelan K, Lindsay JO Evidence for the use of probiotics and
    prebiotics in inflammatory bowel disease: a review of clinical trials. Proc
    Nutr Soc 2007
  • 66 (3): 307-315
    McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM,
    Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ.
    Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn's
    disease. J Clin Invest. 2015
  • 125(8):3215-25.
    Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ,
    Pessoa-Lopes P, Mathew CG, Sanderson JD, Hart AL, Kamm MA, Knight SC, Forbes
    A, Stagg AJ, Lindsay JO, Whelan K. Smokers with active Crohn's disease have a
    clinically relevant dysbiosis of the gastrointestinal microbiota Inflammatory
    Bowel Diseases 2012
  • 18(6): 1092–1100
    Goodhand J, Hedin CR, Croft NM, Lindsay JO. Adolescents with IBD: The
    importance of structured transition care. Journal of Crohn's and Colitis
    2011
  • 5(6): 509-519
    Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA,
    Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, and Lindsay JO A
    randomised, double blind placebo controlled trial of fructo-oligosaccharides
    in active Crohn’s disease. Gut 2011
  • 60: 923-929
    Hedin CRH. In: Smith P, Gill J, Nijjer S, and Levy J, eds. Secrets of
    Success: Getting into academic training. 1 ed. Royal Society of Medicine
    Press Ltd, 2010.

Articles

All other publications

News from KI

Events from KI